View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 F...

American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 Financial Results SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “company”) today reported financial results for its fourth quarter and year ended December 31, 2025. Fourth Quarter Highlights Net income available to common stockholders of $3.1 million and $55.6 million for the three months and year ended December 31, 2025, respectively, or $0.05 and $0.92 per diluted share, respectively.FFO of $0.47 and $2.00 per diluted share for the three months and year ended December 3...

 PRESS RELEASE

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pu...

 PRESS RELEASE

American Assets Trust, Inc. Releases Tax Status of 2025 Distributions

American Assets Trust, Inc. Releases Tax Status of 2025 Distributions SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the tax treatment of its 2025 dividend distributions as follows: Security Descriptions: Common StockCUSIP: 024013104Ticker Symbol: AAT Record DatePayable DateTotal Distribution Per ShareAllocable to 2025Taxable Ordinary DividendLT Capital GainUnrecaptured Sec. 1250 GainSection 199A DividendsReturn of Capital03/06/2503/20/25$0.340$0.340$0.140480$0.059651$0.042897$0.140480$0.13986906/05/2506/19/25$0.340$0....

 PRESS RELEASE

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025...

American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2025 earnings in a press release to be issued after the market closes on Tuesday, February 3, 2026. Senior management will hold a conference call for its fourth quarter and year-end 2025 earnings on Wednesday, February 4, 2026 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 a...

 PRESS RELEASE

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pu...

First Us Bancshares Inc: 2 directors

Two Directors at First Us Bancshares Inc bought 8,005 shares at between 13.659USD and 13.800USD. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ...

 PRESS RELEASE

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Co...

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, In...

 PRESS RELEASE

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a gra...

 PRESS RELEASE

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Di...

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering p...

 PRESS RELEASE

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing ...

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highli...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

TELA Bio to Announce Third Quarter 2025 Financial Results

TELA Bio to Announce Third Quarter 2025 Financial Results MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInve...

 PRESS RELEASE

TELA Bio Appoints William Plovanic to Board of Directors

TELA Bio Appoints William Plovanic to Board of Directors MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity ...

 PRESS RELEASE

American Assets Trust, Inc. Reports Third Quarter 2025 Financial Resul...

American Assets Trust, Inc. Reports Third Quarter 2025 Financial Results Net income available to common stockholders of $4.5 million and $52.5 million for the three and nine months ended September 30, 2025, respectively, or $0.07 and $0.87 per diluted share, respectively. Funds from Operations ("FFO") of $0.49 and $1.53 per diluted share for the three and nine months ended September 30, 2025, respectively. Increased 2025 FFO per diluted share guidance to a range of $1.93 to $2.01 with a midpoint of $1.97, a $0.02 increase over prior guidance. SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) ...

 PRESS RELEASE

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors ...

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and ...

 PRESS RELEASE

American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Rele...

American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, October 28, 2025. Senior management will hold a conference call for its third quarter 2025 earnings on Wednesday, October 29, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust,...

 PRESS RELEASE

TELA Bio Reports Second Quarter 2025 Financial Results

TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix produ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch